CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Nico Lehmann

Director of Biomaterial Processing Innovation, Roche

The Next Wave of Biomaterials in Europe

Director of Biomaterial Processing Innovation

Director of Biomaterial Processing Innovation

Europe's materials world braces for a biomaterial revolution. Forget plant-based plastics, this wave harnesses nature's intelligence for self-healing, adaptive materials that redefine sustainability and performance.


Europe is on the brink of experiencing a new wave in material sciences - the third wave of biomaterials. This movement represents a significant shift in the types of materials being used and how they are perceived and interacted with. The third wave of biomaterials represents a significant leap forward from substituting petroleum-based plastics with plant-derived alternatives. It harnesses biological systems' inherent intelligence and adaptability to create high-performance materials with unparalleled sustainability credentials.


These biomaterials possess remarkable properties, such as self-healing, adapting to their environment, and seamlessly integrating with living tissues. This transformative approach opens up possibilities for creating innovative and eco-friendly materials that can revolutionise various industries. Picture an automotive interior seamlessly tailored to personal comfort, resembling a refined second skin. It precisely regulates temperature and pressure, ensuring optimal support. Consider surgical implants that organically grow within the body, mitigating the risk of rejection. These are mere glimpses of the future heralded by the third wave of biomaterials.


The driving force behind this biomaterial revolution lies in sustainability. Europe, known for its commitment to environmental stewardship, is at the forefront of this movement. Biomaterials offer a pathway away from resource-intensive and pollution-generating extraction and production processes. Using renewable resources such as bacteria, fungi, and plant cells, biomaterials minimise environmental impact and contribute to the circular economy.


 


The appeal of these biomaterials extends beyond their eco-friendliness. They possess remarkable properties that surpass those of traditional materials. Picture textiles are stronger than steel, lighter than air or bioplastics that conduct electricity, and are self-heal-like living tissue. The possibilities are truly limitless.


Europe holds a unique advantage in capitalising on this biomaterial boom. With its strong research institutions, innovative startups, and forward-thinking industrial players, the continent provides fertile ground for collaboration and development. European countries, from Denmark's pioneering research in cellulose nanofibrils to Germany's expertise in bioplastics, bring diverse strengths to the table. Nevertheless, challenges remain on the path to fully realising the potential of this biomaterial wave.


Scaling up production, ensuring long-term stability, and navigating regulatory obstacles are among the hurdles that must be overcome. Collaboration is key to unlocking the full potential of this wave. Public-private partnerships, cross-border research initiatives, and investments in education and training programs are crucial for nurturing the next generation of biomaterial pioneers.


The arrival of the third wave of biomaterials in Europe signifies a turning point in pursuing a sustainable and prosperous future. These intelligent and adaptable materials have the potential to redefine industries, reshape our relationship with the environment, and enhance human health and well-being. As Europe embraces this biomaterial revolution, the rest of the world will undoubtedly observe with awe and inspiration.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://life-science-testing-europe.lifesciencesreview.com/leadership-perspective/the-next-wave-of-biomaterials-in-europe-nwid-1685.html